Sanofi Enters Exclusive Talks to Sell 50% Stake in Opella to CD&R

Sanofi's Exclusive Negotiations with Clayton Dubilier & Rice

Sanofi (NASDAQ: SNY) announced on Monday that it has entered exclusive negotiations to sell a 50% controlling stake in its consumer health division, Opella, to the U.S. private equity firm Clayton Dubilier & Rice (CD&R). This strategic move reflects Sanofi's ongoing efforts to optimize its portfolio and focus on core operations.

Valuation and Investment Details

The Opella business is valued at approximately €16 billion ($17.38 billion), equating to 14 times its expected EBITDA for 2024. Additionally, the French public investment bank, Bpifrance, is anticipated to acquire a stake of around 2%, further solidifying the financial backing of this transaction.

Transaction Timeline and Approvals

The proposed sale is subject to definitive agreements and customary statutory approvals. If all goes according to plan, the transaction is expected to close by the second quarter of 2025 at the earliest, marking a significant milestone for both Sanofi and CD&R.

As the negotiations progress, stakeholders will be closely monitoring the developments surrounding this transaction, given its potential impact on Sanofi's market position and future growth strategies.